Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer

References

• BaumMBudzarAUCuzickJAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialLancet200235993242131213912090977
   PubMed Web of Science ®Google Scholar
• JohnstonSRHeadJPancholiSIntegration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancerClin Cancer Res200391 Pt 2524S532S12538510
   PubMed Web of Science ®Google Scholar
• SchiffRMassarwehSShouJBreast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate responseClin Cancer Res200391 Pt 2447S454S12538499
   PubMed Web of Science ®Google Scholar
• ElledgeRMGreenSCioccaDHER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group StudyClin Cancer Res1998417129516946
   PubMed Web of Science ®Google Scholar
• YamauchiHStearnsVHayesDFWhen is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancerJ Clin Oncol20011982334235611304787
   PubMed Web of Science ®Google Scholar
• StalOBorgAFernoMErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancerAnn Oncol200011121545155011205461
   PubMed Web of Science ®Google Scholar
• FitzgibbonsPLPageDLWeaverDPrognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999Arch Pathol Lab Med2000124796697810888772
   PubMed Web of Science ®Google Scholar
• HurlimannJChaubertPBenhattarJp53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniquesMod Pathol1994744234288066070
   PubMed Web of Science ®Google Scholar
• KernsBJJordanPAMooreMBp53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistryJ Histochem Cytochem1992407104710511607637
   PubMed Web of Science ®Google Scholar
• YamashitaHNishioMToyamaTCoexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancerBreast Cancer Res200461R24R3014680497
   PubMed Web of Science ®Google Scholar
• Kandioler-EckersbergerDLudwigCRudasMTP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patientsClin Cancer Res200061505610656431
   PubMed Web of Science ®Google Scholar
• ThorADBerryDABudmanDRerbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancerJ Natl Cancer Inst19989018134613609747866
   PubMed Web of Science ®Google Scholar
• GeislerSLonningPEAasTInfluence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancerCancer Res20016162505251211289122
   PubMed Web of Science ®Google Scholar
• AasTBorresenALGeislerSSpecific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNat Med1996278118148673929
   PubMed Web of Science ®Google Scholar
• RahkoEBlancoGSoiniYA mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patientsEur J Cancer200339444745312751374
   PubMed Web of Science ®Google Scholar
• ClahsenPCvan de VeldeCJDuvalCp53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancerJ Clin Oncol19981624704799469330
   PubMed Web of Science ®Google Scholar
• BertheauPPlassaFEspieMEffect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapyLancet2002360933685285412243922
   PubMed Web of Science ®Google Scholar
• AskmalmMSCarstensenJNordenskjoldBOlssonBRutqvistLESkoogLStalOMutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patientsActa Oncol200443323524415244246
   PubMed Web of Science ®Google Scholar
• AnderssonJLarssonLKlaarSWorse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMFAnn Oncol200516574374815802278
   PubMed Web of Science ®Google Scholar
• GeislerSBorresen-DaleALJohnsenHTP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancerClin Cancer Res20039155582558814654539
   PubMed Web of Science ®Google Scholar
• KnoopASBentzenSMNielsenMMValue of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patientsJ Clin Oncol200119143376338411454885
   PubMed Web of Science ®Google Scholar
• BerryDAMussHBThorADHER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancerJ Clin Oncol200018203471347911032587
   PubMed Web of Science ®Google Scholar
• ElledgeRMGreenSHowesLbcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group studyJ Clin Oncol1997155191619229164202
   PubMed Web of Science ®Google Scholar
• ArcherSGEliopoulosASpandidosDExpression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapyBr J Cancer1995725125912667577479
   PubMed Web of Science ®Google Scholar
• BernsEMKlijnJGvan PuttenWLp53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancerJ Clin Oncol19981611211279440732
   PubMed Web of Science ®Google Scholar
• KaiKNishimuraRMatsudaMP53 overexpression is a significant factor in predicting resistance to 3rd generation aromatase inhibitors (AIs) in hormone-sensitive recurrent or advanced breast cancerJ Clin Oncol (Meeting Abstracts)20052316715
   Web of Science ®Google Scholar
• SilvestriniRBeniniEDaidoneMGp53 as an independent prognostic marker in lymph node-negative breast cancer patientsJ Natl Cancer Inst19931685 (12):965–970.
   Google Scholar
• EllisMJDingLShenDWhole-genome analysis informs breast cancer response to aromatase inhibitionNature2012486740335336022722193
   PubMed Web of Science ®Google Scholar
• HalevyOMichalovitzDOrenMDifferent tumor-derived p53 mutants exhibit distinct biological activitiesScience199025049771131162218501
   PubMed Web of Science ®Google Scholar
• DittmerDPatiSZambettiGGain of function mutations in p53Nat Genet19934142458099841
   PubMed Web of Science ®Google Scholar
• MukhopadhyayTRothJAA codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53Cancer Res19935318436243668364931
   PubMed Web of Science ®Google Scholar
• BerghJNorbergTSjogrenSLindgrenAHolmbergLComplete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapyNat Med1995110102910347489358
   PubMed Web of Science ®Google Scholar
• BernsEMFoekensJAVossenRComplete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancerCancer Res20006082155216210786679
   PubMed Web of Science ®Google Scholar
• HuppTRMeekDWMidgleyCALaneDPRegulation of the specific DNA binding function of p53Cell19927158758861423635
   PubMed Web of Science ®Google Scholar
• FinlayCAHindsPWTanTHEliyahuDOrenMLevineAJActivating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-lifeMol Cell Biol1988825315392832726
   PubMed Web of Science ®Google Scholar
• ChangFSyrjanenSTervahautaASyrjanenKTumourigenesis associated with the p53 tumor suppressor geneBr J Cancer19936846536618398688
   PubMed Web of Science ®Google Scholar